Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study

Licia Grazzi, Gabriella Egeo, Eric Liebler, Anna Maria Padovan, Piero Barbanti

Research output: Contribution to journalArticle

Abstract

Recent clinical experiences and clinical trials have demonstrated the safety, tolerability, and efficacy of non-invasive vagus nerve stimulation (nVNS; gammaCore®) for the acute and prophylactic treatment of migraine. nVNS has a favorable adverse event profile, making it an attractive option for sensitive patient populations. We explored the safety, tolerability, and efficacy of nVNS as acute migraine treatment in adolescents. A group of adolescent patients suffering from migraine without aura were trained to use gammaCore to manage their migraine attacks. 46.8% of the treated migraine attacks (22/47) were considered successfully treated and did not require any rescue medication. No device-related adverse events were recorded. This preliminary study suggests that nVNS may represent a safe, well-tolerated, and effective for acute migraine treatment in adolescents.

Original languageEnglish
Pages (from-to)197-199
Number of pages3
JournalNeurological Sciences
Volume38
DOIs
Publication statusPublished - May 1 2017

Keywords

  • gammaCore device
  • Migraine without aura
  • nVNS approach
  • Symptomatic treatment
  • Young age

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study'. Together they form a unique fingerprint.

  • Cite this